Harnessing AI and omics for next-generation gene therapy manufacturing

“To make AI and ML truly effective, it is essential to integrate domain-specific knowledge.”

Abi Pinchbeck, Editor, Cell & Gene Therapy Insights, speaks to Richard D Braatz, Chief Scientist and Co-founder of BioCurie, and Irene Rombel, CEO and Co-founder of BioCurie, about their work in AI-driven software and omics technologies to optimize gene therapy production. They discuss the untapped opportunities in integrating omics data, improving efficiencies, and leveraging AI to enhance therapeutic accessibility.

Please enter your email to access content Read now